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For many years deficiency of vitamin D was merely identified and assimilated to the presence of bone rickets. It is now clear
that suboptimal vitamin D status may be correlated with several disorders and that the expression of 1-𝛼-hydroxylase in tissues
other than the kidney is widespread and of clinical relevance. Recently, evidence has been collected to suggest that, beyond
the traditional involvement in mineral metabolism, vitamin D may interact with other kidney hormones such as renin and
erythropoietin. This interaction would be responsible for some of the systemic and renal effects evoked for the therapy with
vitamin D. The administration of analogues of vitamin D has been associated with an improvement of anaemia and reduction
in ESA requirements. Moreover, vitamin D deficiency could contribute to an inappropriately activated or unsuppressed RAS, as
a mechanism for progression of CKD and/or cardiovascular disease. Experimental data on the anti-RAS and anti-inflammatory
effects treatment with active vitaminD analogues suggest a therapeutic option particularly in proteinuric CKDpatients.This option
should be considered for those subjects that are intolerant to anti-RAS agents or, as add-on therapy, in those already treated with
anti-RAS but not reaching the safe threshold level of proteinuria.
1. Introduction
The kidney has an important role in the regulation of several
systems. In addition to excretory activity, regulation of water
and electrolytes, and maintaining normal acid-base homeo-
stasis, the kidney has also an endocrine function. It is carried
out through the production of important hormones: renin,
prostaglandins, erythropoietin, and calcitriol.
Renin is released from the renal juxtaglomerular appa-
ratus (JGA). Renin production is regulated by three major
mechanisms: change in renal perfusion pressure, solute
delivery to the macula densa cells, and influence of renal
sympathetic nerves. The negative effects of the activation of
renin-angiotensin system on the progression of renal failure
are well known. Indeed, blockade of the renin-angiotensin
system is awidely established and utilized antiproteinuric and
renoprotective modality [1, 2].
Moreover, it has been suggested that the dual-block
therapymight improve outcome by preventing compensatory
feedback processes that generate more angiotensin II when
a single blocker is used. Indeed a number of studies on the
progression of renal diseasewere focused on the role of block-
ing the activation of the renin-angiotensin system (RAS),
to reduce the loss of glomerular filtration rate and delay
the start of dialysis, even though the results on the safety
of this intervention do suggest caution on the “aggressive”
suppression of RAS [3, 4]. However, a reduced efficacy
of RAS inhibitors is due to the compensatory increase of
renin synthesis caused by the disruption of the feedback
inhibition loop. Renin build-up in fact not only stimulates
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Figure 1: Traditional and nontraditional effects of active vitamin D.
the conversion of Ang I leading to Ang II accumulation but is
also likely associatedwith detrimental effects directly induced
by renin [5]. In this context it is important to value the role
of vitamin D. Experimental evidence in fact has accumulated
on vitamin D-related blunting of the compensatory increase
of renin synthesis occurring during chronic administration of
anti-RAS agents [6, 7]. In particular, in experimental diabetes,
block of the compensatory increase of renin expression by
vitamin D analogs dramatically increases the therapeutic
efficacy of RAS inhibition (Figure 1) [7]. Beyond the known
effect on blood pressure recent studies provided valuable
insight into the nonhemodynamic actions of Ang II and other
components of the RAS in the progression of kidney disease
[8].
In patients with chronic renal disease, a slow, gradual
decrease in the level of 1,25-dihydroxyvitamin D (calcitriol)
and erythropoietin is observed whilst different mechanisms
bring to increased activation of the renin-angiotensin system
[9]. The main complications of erythropoietin and 1,25-
dihydroxyvitamin D (calcitriol) deficiency are in fact anemia
and secondary hyperparathyroidism. Renal anemia is due
to a reduced production of erythropoietin by interstitial
fibroblast in the renal cortex, between tubular epithelial
cells and peritubular capillaries [10]. The origin of decreased
serum levels of 1,25(OH)2D is multifactorial. The leading
cause is a decrease in renal mass, which causes a consequent
reduction in the level of 1-𝛼-hydroxylase available for the pro-
duction of active vitamin D. In CKD, hyperparathyroidism
and hyperphosphoremia can contribute to inhibit the renal
bioactivation of vitamin D.
While single effects of the different renal hormones are
well known, less information is available regarding the inter-
action between them. Recently, a number of studies suggested
that vitamin D interplays with both renin-angiotensin sys-
tem and erythropoietin [11, 12]. This interaction would be
responsible for some of the systemic and renal effects which
has recently been implicated for vitamin D. In particular,
the interplay between renal hormones produces its effects on
hypertension and proteinuria [13].
2. Vitamin D and Erythropoietin
Recent clinical observations suggest a possible role of vitamin
D in erythropoiesis [14]. In the hemodialysis population, 1-
25(OH)D repletion has been associated with dose reductions
in erythrocyte-stimulating agents (ESA) and increased retic-
ulocytosis [15, 16].
In CKD patients, the administration of either nutritional
or active vitaminD has been associated with an improvement
of anaemia and reduction in ESA requirements [17].
Despite these intriguing observations, there is overall
paucity of clinical studies investigating whether adequacy of
1-25(OH)D affects blood hemoglobin (Hb) levels. Patel et al.
show that 25D and 1,25Ddeficiency are independently associ-
ated with decreased hemoglobin levels and anemia in chronic
kidney disease. They measured the concentrations of 25-
hydroxyvitamin D (25D), 1,25-dihydroxyvitamin D (1,25D),
and hemoglobin in a cross-sectional study of 1661 subjects in
SEEK, a multicenter cohort study of chronic kidney disease
patients in theUnited States, of whom41%met the criteria for
anemia. The mean hemoglobin concentrations significantly
decreased with decreasing tertiles of 25D and 1,25D. These
linear trends remained significant after adjustment for age,
gender, ethnicity, eGFR, diabetes, and PTH [12].
To evaluate the prevalence of anemia in a population of
individuals with vitamin D deficiency, Sim et al. studied for
two years 554 subjects in a general population as part of
normal healthcare operations. Anemia was present in 49% of
25(OH)D-deficient subjects comparedwith 36%with normal
25(OH)D levels (𝑃 < 0.01). 25(OH)D-deficient subjects had a
lower mean Hb levels (11.0 versus 11.7; 𝑃 = 0.12) and a higher
prevalence of ESA use (47% versus 24%;𝑃 < 0.05).This study
demonstrates an association between vitamin D deficiency,
greater risk of anemia, lower mean hemoglobin, and higher
use of ESA [18].
In end-stage heart failure subjects, vitamin D deficiency
has been showed to be independently associated with low
Hb values and anemia. In these subjects, the mean Hb
concentrationswere significantly reduced in the lower tertiles
of 25(OH)D and 1,25(OH)2D (𝑃 < 0.001). The odds ratios
for anemia of the lowest tertile of 25(OH)D (<18 nmol/L)
and 1,25(OH)2D (<40 pmol/L) were 2.69 (1.46–5.00) and
4.08 (2.18–7.62) compared with their respective highest tertile
(>32 nmol/L and >70 pmol/L). Patients with severe dual defi-
ciency of 25(OH)D and 1,25(OH)2D had an odds ratio for
anemia of 9.87 (95% CI 3.59–27.1) compared with patients in
the highest tertile for both vitamin D metabolites [19].
Although vitamin D appears to be associated with ane-
mia, the mechanism is unknown.
A reverse correlation was found between PTH and Hb
level [20]. Possible causes of low Hb level or anemia due to
SHPT may be because of increased bone marrow fibrosis,
which may lead to decreased erythropoietin and increased
resistance to EPO [21]. Erythropoietin cells express calcitriol
receptors, which induces proliferation and maturation of
erythroid progenitor cells. Therefore, deficiency of calcitriol,
a cause of hyperparathyroidism, may impair erythropoiesis
(Figure 1). There are also some studies, which support
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an increase in erythrocyte osmotic fragility due to high
concentration of PTH in patients on dialysis, leading to low
Hb level [22]. There is also indirect evidence of restoration
of the hematocrit after parathyroidectomy in uremic patients
due to restoration of bone marrow space after operation
and rise of immunoreactive erythropoietin (EPO) serum
concentrations [23]. Icardi et al. on the contrary consider that
these effects are not related to parathyroid hormone (PTH)
values and seem to be independent of PTH suppression [24].
The majority of studies concerning vitamin D deficiency
or supplementation, and degree of renal anaemia, point out
the prevalent role of inflammation in the mechanism under-
lying these associations. Immune cells express the vitamin D
receptor (VDR) which in turn is involved in the modulation
of innate and adaptive immunity. Both in vivo and in vitro
studies have demonstrated that calcitriol reduces cytokines
production [25]. VDR activation inhibits the expression of
inflammatory cytokines in stromal and accessory cells and
upregulates the lymphocytic release of interleukin-10 (IL-
10) exerting both anti-inflammatory activity and proliferative
effects on erythroid progenitors. In CKD patients, vitamin
D deficiency may stimulate immune cells within the bone
marrow microenvironment to produce cytokines, inducing
impaired erythropoiesis. Immune activation involves the
reticuloendothelial system, increasing hepcidin synthesis and
functional iron deficiency [24]. Recently Zughaier et al.
showed that 1,25-dihydroxyvitamin-D(3) (1,25(OH)2D3),
the hormonally active form of vitamin D, is associated
with decreased hepcidin and increased ferroportin expres-
sion in lipopolysaccharide (LPS) stimulated THP-1 cells.
1,25(OH)2D3 also resulted in a dose-dependent decrease
in prohepcidin cytokines, IL-6, and IL-1𝛽, release in vitro.
Further, they show that high-dose vitamin D therapy impacts
systemic hepcidin levels in subjects with early stage CKD.
These data suggest that improvement in vitamin D status is
associated with lower systemic concentrations of hepcidin in
subjects with CKD [26].
Another possible explanation may be that calcitriol
directly stimulates erythroid progenitors; vitamin D has been
demonstrated to affect bone marrow function [27, 28].
Furthermore, levels of 1,25 hydroxyvitamin D (1-
25(OH)2D), the active form of vitamin D, are several hun-
dredfold higher in bone marrow compared with plasma [25].
Aucella et al. have shown that administration of 1,25(OH)2D
increased burst-forming unit erythroid proliferation in
patients with ESRD. Calcitriol has a direct effect on erythroid
precursors proliferation, as demonstrated both in vitro and
in vivo, with a synergistic effect with epoetin alfa [29].
Vitamin D receptors have been discovered in numerous
nonrenal target tissues including the bone marrow [27, 28].
Normalizing tissue 25(OH)D levels may provide an adequate
substrate for local tissue production of 1,25(OH)2D in hema-
topoietic tissues via extra-renal tissue activity of the 1-alpha-
hydroxylase enzyme. Hematons, the buffy coat of bone mar-
row containing erythroid precursors, fibroblast, endothelial
cells, lipid laden cells, and macrophages, have been demon-
strated to contain significantly higher concentrations of
25(OH)Dand1,25(OH)2Dlevels than bonemarrowplasma [16].
High local concentrations of 1,25(OH)2D in hematopoietic
tissues may then directly activate erythroid precursor cells
in a paracrine fashion.
In conclusion, only few studies with a limited number of
patients explored the association between vitamin D defi-
ciency and anemia in CKD patients. In addition, the molec-
ular evidence about the role of calcitriol in erythropoiesis is
still very limited.
3. Vitamin D and Renin-Angiotensin-
Aldosterone System
The renin-angiotensin-aldosterone system (RAS) plays a cen-
tral role in the regulation of blood pressure, electrolyte, and
volume homeostasis. Epidemiological and clinical studies
have repeatedly evidenced the impact of vitamin D on RAS
activity at the clinical, pathophysiological, and molecular
level.
RAS includes a cascade that leads to the generation of
angiotensin II (Ang II), the main effector of the system. The
rate-limiting component of the RAS is renin, a highly specific
aspartic peptidase synthesized and secreted predominantly
by the juxtaglomerular (JG) cells in the nephron. The only
known substrate of renin is angiotensinogen, which is enzy-
matically cleaved to angiotensin I by renin. Angiotensin I
is further cleaved to Ang II by the angiotensin converting
enzyme (ACE) [11].
Ang II exerts diverse actions inmultiple organs, including
the brain, heart, kidney, adrenal glands, and peripheral vas-
culature, to regulate the blood pressure and electrolyte and
extracellular volume balance and inappropriate stimulation
of the RAS has been associated with hypertension, heart
attack, and stroke [30, 31].
The relationship between vitamin D and blood pressure
and/or plasma renin activity has been debated in many
studies. The first clinical studies suggesting an inverse rela-
tionship between calcitriol and renin levels were published
by Burgess, Resnick et al. more than two decades ago [32, 33].
This correlation was recently confirmed in a large cohort
study of CKD patients by Forman et al. They examined the
relation between plasma 25-hydroxyvitamin D and elements
of the RAS in 184 normotensive individuals in high sodium
balance; these included circulating levels of plasma renin
activity and Ang II, and the renal plasma flow response
to infused Ang II, which is an indirect measure of the
intrinsic RAS activity in the kidney. Compared to individuals
with sufficient 25-hydroxyvitamin D levels (≥30 ng/mL),
those with insufficiency (15–29.9 ng/mL) and deficiency
(<15 ng/mL) had higher circulating Ang II levels (𝑝-trend =
0.03). Moreover, those with vitamin D deficiency had sig-
nificantly blunted renal plasma flow responses to infused
Ang II (mean decrease of 115mL/min/1.73m2 in renal plasma
flow versus 145mL/min/1.73m2 among those with sufficient
vitamin D levels; 𝑃 value = 0.009). Although plasma renin
activity was higher among individuals with insufficient levels
of vitamin D, the result was not statistically significant.These
data suggest that low plasma 25-hydroxyvitamin D levels
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may result in upregulation of the RAS in otherwise healthy
humans [34, 35].
Furthermore Park et al. studied fifteen hemodialysis
patients with secondary hyperparathyroidism. They showed
that, in patients receiving calcitriol, levels of plasma renin
(18.5/−12.7 v 12.3/−11.0 pg/mL; 𝑃 = 0.007) and angiotensin
II (AT N; 79.7/−48.6 v 47.2/−45.7 pg/mL; 𝑃 = 0.001) were
significantly decreased [36].
Several mechanistic studies confirming negative regula-
tion of the renin gene by calcitriol have been published
by the group of Li et al., who showed that renin expression
and plasma angiotensin II productionwere increased several-
fold in vitamin D receptor-null (VDR-null) mice, leading
to hypertension, cardiac hypertrophy, and increased water
intake. In wild-type mice, inhibition of 1,25-dihydroxyv-
itamin-D(3) synthesis also led to an increase in renin expres-
sion, whereas 1,25-dihydroxyvitamin-D(3) injection led to
renin suppression [37]. In another study they demonstrated
that suppression of renin expression by 1,25-dihydroxyv-
itamin D in vivo is independent of parathyroid hormone
(PTH) and calcium [38]. To explore the molecular mech-
anism, they analyzed the mouse Ren-1c gene promoter by
luciferase reporter assays. The data obtained indicate that
calcitriol binds to the VDR and subsequently blocks for-
mation of the cyclic adenosine monophosphate-response
element-binding protein (CRECREB- CBP) complexes in
the promoter region of the renin gene, reducing its level of
expression [39].
Studies on suppression of renin-angiotensin gene expres-
sion in the kidney by paricalcitol were also conducted.
Freundlich et al. studied rats with the remnant kidney model
of chronic renal failure (5/6 nephrectomy) towhich have been
given two different doses of paricalcitol thrice weekly for 8
weeks. Paricalcitol was found to decrease angiotensinogen,
renin, renin receptor, and vascular endothelial growth factor
mRNA levels in the remnant kidney by 30–50 percent com-
pared to untreated animals. Similarly, the protein expressions
of renin, renin receptor, the Ang type 1 receptor, and vascular
endothelial growth factor were all significantly decreased.
Glomerular and tubulointerstitial damage, hypertension,
proteinuria, and the deterioration of renal function result-
ing from renal ablation were all similarly and significantly
improved with both treatment doses [40].
In a recent study Fryer et al. show that, in C57/BL6 mice
administered vehicle, paricalcitol produces significant, dose-
dependent suppression of renin expression in the absence
of hypercalcemia at doses 10-fold above those necessary for
PTH suppression. Calcitriol also produced suppression of
renin at doses at least 10-fold above those required for PTH
suppression, but increases in iCa(2+) were observed at doses
only 3-fold above those necessary to elicit renin suppression.
Interactions between vitamin D and other system RAAS
components have been studied as well [41].
Aldosterone binds mineralocorticoid receptor, which
belongs to the same superfamily of nuclear receptors as the
VDR.Therefore, cross talk between these receptors and their
agonists could potentially exist. Fischer et al. observed that
plasma concentration of 1,25-dihydroxyvitamin-D(3) and
aldosterone were significantly higher in mice that are genet-
ically deficient for klotho, a membrane protein participating
in the inhibitory effect of fibroblast growth factor-23 (FGF23)
on the formation of 1,25-dihydroxyvitamin-D(3). High levels
of calcitriol were associated with hyperaldosteronism, which
is similarly reversed by a vitamin D-deficient diet [42]. Fur-
thermore Good et al. identified a novel regulatory interaction
whereby aldosterone acts via nongenomic mechanisms to
enhance the genomic response to 1,25-dihydroxyvitamin-
D(3). Aldosterone may influence a broad range of biological
processes, including epithelial transport, by modifying the
response of target tissues to 1,25-dihydroxyvitamin-D(3)
stimulation [43].
It has been demonstrated that low vitamin D status
adversely affects cardiac function. This effect of vitamin
D seems to be mediated by the renin-angiotensin system.
Indeed, VDR-knockout mice show myocardial renin overex-
pression and marked cardiomyocyte hypertrophy [44].
Despite many studies suggested that vitamin D may
favorably influence myocardial hypertrophy, two large ran-
domized clinical trials have shown that VDR activation did
not influence or reverse left ventricular hypertrophy [45, 46].
In particular in the PRIMO trial, which included 227 patients
with CKD stages 3 to 4 who were randomized to paricalcitol
or placebo, the change in left ventricular mass index after 12
months did not differ between the two groups [45]. Similar
results were reported in the OPERA trial, where patients
with 3 to 5 CKD were randomly assigned to receive oral
paricalcitol or placebo. After 52 weeks, VDR activation with
paricalcitol failed to demonstrate any change in the measures
of LV structure and function. However in both studies the
authors found a correlation between VDR activation and
hospitalization for cardiovascular events [46]. Interestingly a
post hoc analysis of PRIMO trial has demonstrated that forty-
eight weeks of therapy with paricalcitol significantly reduces
left atrial volume and attenuates the rise of brain natriuretic
peptide (Figure 1) [47].
Chronic kidney disease (CKD) is a public health priority
due to the prevalence rates, around 10% in general adult
population, and the ominous and costly cardiorenal outcome
[48]. Nowadays, albuminuria is widely considered the main
“modifiable” risk factor of global prognosis in CKD patients.
Even moderate increases of albuminuria in fact remarkably
enhance the risk of end-stage renal disease (ESRD) and
all-cause and cardiovascular (CV) death independently of
age, hypertension, and diabetes [49, 50]. More important, a
recent study in a cohort of 638,150 adults from a province-
wide registry in Alberta, Canada, has demonstrated that
proteinuria of increasing severity is associated with a faster
rate of renal decline regardless of baseline eGFR [51]. A
similar main independent prognostic role of proteinuria has
been confirmed in the specific setting of tertiary nephrology
care [52, 53]. Indeed, the new classification of CKD recently
issued by KDIGO highlights the major role of albuminuria
[54].
On the other hand, a decrease of proteinuria follow-
ing therapeutic interventions with anti-RAS agents heralds
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a better renal prognosis over time in most patients, even in
those starting with moderate proteinuria [55–57].
Therefore, albuminuria (or proteinuria) identifies pa-
tients at risk for adverse clinical outcomes and efficacious
antiproteinuric (antialbuminuric) approaches improve long-
term prognosis. Inhibition of the renin-angiotensin system
(RAS) certainly is the cornerstone of treatment in protein-
uric patients with the effect being largely independent of
blood pressure control [58]. However, the high complex-
ity of the system with multiple-level escape mechanisms
prevents adequate suppression. Indeed, monotherapy with
either angiotensin converting enzyme inhibitor (ACEi) or
angiotensin receptor blocker (ARB) decreases proteinuria by
not more than 20–30% [59]. Combined use of ACEi and ARB
can be an efficacious strategy to further decrease proteinuria
especially in nondiabetic CKD [60], but safety issues prevent
wider implementation of dual blockade [3, 4].
Novel antiproteinuric strategies aimed at attaining remis-
sion of proteinuria (<0.5 g/24 h) are actively being sought.
Under this point of view, of great interest are the experimental
data linking vitaminDwith albuminuria bymeans of its anti-
RAS and anti-inflammatory effects [5, 13, 61].
Recent interventional studies have disclosed that nutri-
tional vitaminD repletion or administration of active vitamin
D, that is, a less potent and more calcemic vitamin D ana-
log [62], reduces proteinuria in patients with milder de-
grees of renal disease, such as microalbuminuric diabetic
nephropathy with moderate GFR impairment and IgA
nephropathy with close-to-normal GFR [63, 64]. In patients
with more advanced disease (CKD stages 3 to 5 and/or
macroalbuminuria-proteinuria), consistent data on antipro-
teinuric effect (−30% on average) have been almost exclu-
sively provided for paricalcitol, an active analogue of vitamin
D with low calcemic effect when used at low dose (1mcg/24
or 48 h), in diabetic as nondiabetic patients with residual
proteinuria after anti-RAS therapy [6, 65–69]. In particular in
vital study, the authors found that the use of paricalcitol was
associated with a reduction of blood pressure, probably for
the previously mentioned effect on renin-angiotensin system
[68].
These data have been consolidated in two recent large
meta-analyses also showing a substantial safety on markers
of mineral bone disease (MBD) of this therapy [70, 71].
The effectiveness of paricalcitol in proteinuric CKD, as
well as the awareness of albuminuria as determinant of poor
renal prognosis in kidney transplant recipients (KTR) [72],
has led investigators to test the antialbuminuric property of
paricalcitol also in KTR patients. Two studies deserve to be
mentioned.The first onewas an observational workwith long
follow-up (up to 24 months) in 58 patients, transplanted by
6 yrs on median, with mean eGFR 35mL/min/1.73m2 and
proteinuria of 1.1 g/24 h [73]. In this study, paricalcitol at the
dose of 1 mcg/48 h induced a 36% reduction of proteinuria
thatwas associatedwith a significantly slower decline of eGFR
during the 24 months of treatment as compared to the 24
months before. More recently, the group headed by Remuzzi
has completed a 6-month randomized controlled trial show-
ing that oral paricalcitol (1 to 2mcg/day) in 43 recipients
of renal transplants with secondary hyperparathyroidism
induced, besides the better control of markers of MBD
obtained in the absence of hypercalcemia-phosphatemia, a
significant reduction of proteinuria (from 0.27 to 0.14 g/24 h
on average) [74].
4. Vitamin D and Hypertension
In the last decade, observational or epidemiologic studies
consistently indicated that hypovitaminosis D is associated
with higher all-cause mortality rates, including those from
cardiovascular diseases [75–77]. In particular, the mean
serum 25-hydroxyvitamin D levels have been reported to
be significantly lower in patients with stable coronary artery
disease than in healthy control subjects and independently
associated with extent and complexity of coronary artery
disease and hypertension [78]. In this regard, previously
reported evidence suggested that vitamin D inadequacy
may be involved in the development of hypertension. The
Third National Health and Nutrition Examination Survey
showed that an inverse relationship existed between 25-
hydroxyvitamin D and systolic blood pressure, and this
relationship remained significant even after adjustment for
age, sex, ethnicity, physical activity, and bodymass index [79].
Moreover, a retrospective analysis of 2 large cohort studies
showed that men whose plasma levels of 25-hydroxyvitamin
Dwere in the lowest (<15 ng/mL) category were at the highest
risk of hypertension relative to men whose levels of 25-
hydroxyvitamin D were in the highest (≥30 ng/mL) category
(relative risk 6.13). In the same comparison with women, the
multivariate relative risk was 2.67 [80].
Among the pathophysiological mechanisms, still largely
unknown, underlying the association between hypovita-
minosis D and hypertension, a key role could be played
by vitamin D-mediated suppression of renin biosynthesis
through regulation of the renin-angiotensin system (RAS)
[37]. Data from animal studies indicated that circulating
active vitamin D may act as an inhibitor of renin expres-
sion in the juxtaglomerular apparatus and vascular smooth
muscle cell proliferation [81]. Vitamin D receptor activation
inhibits intrarenalmRNA levels and protein expression of key
components of RAS (angiotensinogen, renin, renin receptors,
and angiotensin II type 1 receptor) independently of calcium
metabolism in mice and rats [39, 40]. Notably, these findings
have not been replicated in humans since no suppressive
effect on systemic RAS has been found in patients treated
with vitaminD [82] and in essential hypertensives after short-
term calcitriol administration and after long-term chole-
calciferol therapy [83]. However, in both studies, patients
were under treatment with RAS inhibitors. Recently, chronic
vitamin D receptor stimulation by cholecalciferol therapy
has been shown to blunt systemic RAS activity in essential
hypertensive patientswith hypovitaminosisDunder constant
salt intake and free from drugs interfering with RAS [84].
Moreover, comparedwith sufficient vitaminD status, vitamin
D deficiency has been associated with a decreased arterial
response to angiotensin II challenge (increased delta brachial
pulse-wave velocity and delta aortic augmentation index)
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and increased arterial stiffness in healthy humans, possibly
through an angiotensin II-dependent mechanism [85].
Since suboptimal vitamin D levels are linked with devel-
opment of hypertension, it could be assumed that vitamin
D replacement or normalization would reduce the risk of
cardiovascular disease and its effects. Results from interven-
tional studies strongly suggested that vitamin D supplemen-
tation had a great blood pressure lowering effect and overall
improved cardiovascular risk profile [75, 86–88].
The supplementation for 8 weeks with vitamin D plus
calcium in 148 vitamin D-deficient elderly women signif-
icantly lowered systolic blood pressure by 9.3%, while the
calcium-only supplementation lowered it by 4.1% compared
to baseline [86]. These results were confirmed by a sub-
sequent double-blind, parallel group, and placebo-controlled
randomized trial in vitamin D-deficient type 2 diabetes
patients, which were administered with a single dose of
100,000 international units (IU) vitamin D2 or placebo for
8 weeks. Vitamin D supplementation significantly improved
flow mediated vasodilatation (FMD) of the brachial artery
by 2.3% and decreased systolic blood pressure by 14mmHg
compared with placebo.The improvement in FMD remained
significant after adjusting for changes in blood pressure.
However, changes in FMD did not correlate with the reduc-
tion of systolic blood pressure [87]. A positive correla-
tion between FMD and 25(OH)D was also observed in
asymptomatic vitamin D-deficient subjects supplemented
with 300,000 IU monthly for 3 months. FMD measurements
significantly improved after replacement therapy and resulted
significantly lower than controls. Additionally, posttreatment
values of lipid peroxidation indexes were significantly lower
than pretreatment levels, and a negative correlation between
FMD and lipid peroxidation indexes was also observed [88].
Further observations demonstrated that daily supple-
mentation of 2000 IU of vitamin D for 16 weeks optimized
vitamin D levels and significantly improved carotid-femoral
pulse-wave velocity, a cardiovascular surrogate marker, in 49
young black peoplewith vitaminD insufficiency or deficiency
[89].
However, despite the large number of clinical studies car-
ried out to examine the effect of vitamin D supplementation
on blood pressure, no univocal data are available on the
potential antihypertensive effect of vitamin D. As discussed
by a recent meta-analysis on vitamin D supplementation and
cardiovascular events, this might be due to heterogeneity
of patient baseline characteristics, differences in sample
size and follow-up periods, and different vitamin D doses.
Indeed, most of randomized controlled trials of vitamin
D supplementation and blood pressure mainly have given
vitamin D for short periods (<6 months) or at low doses
(400 IU per day) [90]. Moreover, the use of different vita-
min D formulations produced differences in blood pressure
reduction, as shown by ergocalciferol or cholecalciferol with
ultraviolet B demonstrating a greater decrease in systolic
blood pressure (−6.2mmHg) than calcitriol (0.7mmHg)
[75]. Notably, recent findings suggest that the association
between vitamin D status and elevated blood pressure noted
in observational studies may not to be causal. Indeed,
vitamin D supplementation did not reduce blood pressure
in individuals with pre- or stage I hypertension and vitamin
D deficiency [91]. Six months of intermittent, high-dose oral
vitamin D3 supplementation did not reduce blood pressure
or left ventricular mass in patients with resistant hyperten-
sion [92]. Moreover, a long-term (18 months) vitamin D
supplementation, increasing the mean 25-hydroxyvitamin
D3 concentration >100 nmol/L, had no effect on systolic
or diastolic blood pressure in healthy adults without severe
vitamin D deficiency [93].
Essential hypertension is a typical example of a complex,
multifactorial, and polygenic trait where different metabolic
pathways are involved (inflammation, coagulation cascade,
sodium reabsorption, cellular adhesion, and lipid metab-
olism). Some gene variants, contributing to between 30% and
50% of the variation in blood pressure among humans, have
been identified so far that interact with environmental factors
to produce the hypertensive phenotype. Recently, evidence
for an important role of the endothelial vitamin D receptor
(VDR) in regulating endothelial function and blood pressure
has been provided [94].Moreover, VDRgene polymorphisms
(BsmI, ApaI, and FokI) have been shown to be associated
with left ventricle hypertrophy, atherosclerosis, and essential
hypertension [95–98].
A decade ago a study investigating the relationship
between bonemineral density (BMD) and carotid artery inti-
mal medial thickness (IMT), as a surrogate marker of endo-
thelial dysfunction, among 471Mexican women, showed that
forearm BMD and IMT were significantly higher in indi-
viduals having the VDRBsmI BB genotype. Furthermore, the
association of the VDR genotype with IMT was not depend-
ent on the association between VDR and BMD [99]. In con-
trast, no significant difference was detected in biochemical
parameters and physical examination between groups for
BsmI and ApaI VDR gene polymorphisms in a subsequent
study including 74 hypertensive patients (49 females/25
males) without other comorbidities, that is, diabetes mellitus,
impaired glucose tolerance, and severe obesity [100]. Interest-
ingly, a negative correlation was observed between vitamin
D levels and day-time interval and early morning average
blood pressure in the FokI non-FF (Ff/ff, 𝑛 = 35) group
compared with the FF one (𝑛 = 39). Serum cystatin-C was
higher in the non-FF group, and the degree and presence
of retinopathy were significantly higher in the non-FF group
when compared to the FF group [100].
These results were confirmed by a large case-control study
investigating the relationship between the VDR FokI poly-
morphism and essential hypertension in 280 patients and 200
healthy subjects.The risk for hypertension in FFhomozygotes
was found 2.2 times greater than in Ff heterozygotes and
2.2 times greater than in ff homozygotes, regardless of the
presence of family history and smoking statusHowever, when
comparing Ff and ff genotypes, no significant difference was
observed [101].
Recently, a prospective study has been carried out which
aimed to evaluate the association of circulating vitamin D
metabolites, VDR FokI and BsmI gene polymorphisms, and
their interaction with risk of hypertension [102]. Briefly
among the recruited 1,211 US men that were free of base-
line hypertension 695 men developed incident hypertension
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during 15.3-year follow-up. After multivariable adjustment
statistical analysis showed that carriers of VDR BsmI bB or
BB had a relative risk for hypertension increased by 1.25-
fold compared with carriers of bb, while carriers of VDR
FokI ff had a relative risk increased by 1.32-fold compared
with carriers of FF and Ff combined. Moreover, evidence for
an inverse association between plasma 25(OH)D and risk of
hypertension was found even if the relation between plasma
25(OH)D and risk of hypertension did not differ by VDR
BsmI and FokI polymorphisms [102].
Notably, it has been reported that VDR mutant mice
are characterized by lower bioavailability of the vasodilator
nitric oxide (NO) due to reduced expression of endothelial
nitric oxide synthase, leading to endothelial dysfunction,
increased arterial stiffness, increased aortic impedance, struc-
tural remodeling of the aorta, and impaired systolic and
diastolic heart function at later ages, independent of changes
in the renin-angiotensin system [103]. In the light of these
reported observations, it may be assumed that more research
is needed to further evaluate the role of vitamin D polymor-
phisms in hypertension development and the usefulness of
vitamin D supplementation in hypertension prevention.
5. Conclusion
Beyond the traditional involvement in mineral metabolism,
vitamin D may interact with other kidney hormones such as
renin and erythropoietin.This interactionwould be responsi-
ble for some of the systemic and renal effects associated with
VDR activation. The administration of analogues of vitamin
D has been associated with an improvement of anaemia
and reduction in ESA requirements [15–17]. The associations
found in clinical studies and the supporting mechanistic
studies make it plausible that vitamin D deficiency could
indeed contribute to an inappropriately elevated renin levels,
as a mechanism for progression of CKD and/or cardiovas-
cular disease [5–7]. Consequently the beneficial effects of
vitamin D receptor activators in experimental chronic renal
failure could be related to downregulation of the renal renin-
angiotensin system and in particular to a reduced renin build-
up caused by the disruption of the feedback inhibition loop
[5–7].
Studies in large patients series and with adequate follow-
up are definitely needed to confirm the effects of long-
term paricalcitol treatment in CKD and its potential role
in improving renal outcome in comparison with not only
placebo but also other vitamin D metabolites and analogues
[65–74]. Meanwhile, however, it is plausible to suggest that
treatment with active vitamin D analogues represents a
therapeutic option in proteinuric CKD that can be used in
patients intolerant to anti-RAS agents or, as add-on therapy,
in those already treated with anti-RAS but not reaching the
safe threshold level of proteinuria (<0.5 g/24 h) [69].
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